Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582060 · ClinicalTrials.gov registry record · NA
Individualizing Hemophilia Prophylaxis Using Thromboelastography
A NA study, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02582060 is a NA study that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 18 participants.
The verdict
NCT02582060, a NA study, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Currently dosing for prophylaxis is not individualized, and the general approach is to use a dose of 25-40 units/kg given 3 times per week or every other day. One of the issues with weight-based dosing is the possible over-treatment. This is likely due to the fact that laboratory tests are not sensitive enough at the low levels to support decision-making. The Thromboelastograph (TEG®) and Thromboelastometry (ROTEM®) are coagulation devices, which assess the dynamics of clot formation over time and have several characteristics which suggest they may provide important information for individualized prophylaxis treatment for our patients.
Interventions
- OTHER Thromboelastography/Thromboelastometry-Guided Treatment Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-05-20 |
| Est. Completion | 2017-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582060
The ClinicalTrials.gov registry entry for NCT02582060 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thromboelastography/Thromboelastometry-Guided Treatment Regimen is the first listed.
NCT02582060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02582060 about?
NCT02582060 is a clinical study titled "Individualizing Hemophilia Prophylaxis Using Thromboelastography". Currently dosing for prophylaxis is not individualized, and the general approach is to use a dose of 25-40 units/kg given 3 times per week or every other day. One of the issues with weight-based dosing is the possible over-treatment. This is likely due to the fact that laboratory tests are not sensi...
What is the current status of trial NCT02582060?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2014-05-20. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT02582060?
The interventions under investigation include: Thromboelastography/Thromboelastometry-Guided Treatment Regimen (OTHER).
Who is sponsoring clinical trial NCT02582060?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.